

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### Targeted-release budesonide for treating primary IgA nephropathy (ID1434)

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
IgA nephropathy is more prevalent in men than in women and also amongst people with an Asian or Caucasian family background.  It is most commonly diagnosed in young people and people under 40-years old.
2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
In appraising targeted-release budesonide within its marketing authorisation the committee will have the opportunity to consider and address any potential equality issues relating to age, sex and family background. The committee should be mindful of the extent to which their recommendations could disadvantage a particular group.
3. Has any change to the draft scope been agreed to highlight potential equality issues?
No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No

**Approved by Associate Director (name):** Jasdeep Hayre

**Date:** 13 February 2023